Physician profile
Lloyd Brooks Minor
NPI 1801846654
$51,504.91
in general payments reported to CMS, 2019-2025
3 companies · $47K in 2025
The $47K reported for 2025 was more than what 99% of Otology & Neurotology providers received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $4,144 · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $20K · Food and Beverage: $99.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,861.41 |
| Travel and Lodging | $19,544.42 |
| Food and Beverage | $99.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $47,360.78 | 2025 | |
| Merck Sharp & Dohme LLC | $4,144.13 | 2023 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$720,159.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Minor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.